Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

PHASE2UnknownINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

April 30, 1998

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
BIOLOGICAL

oregovomab

Trial Locations (46)

11030

North Shore University Hospital, Manhasset

13210

State University of New York - Upstate Medical University, Syracuse

21201

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

22908

Cancer Center, University of Virginia HSC, Charlottesville

29303

Spartanburg Regional Medical Center, Spartanburg

32209

University of Florida Health Science Center - Jacksonville, Jacksonville

32804

Walt Disney Memorial Cancer Institute, Orlando

33901

Patty Berg Cancer Center, Fort Myers

37901

Baptist Regional Cancer Center - Knoxville, Knoxville

48202

Henry Ford Hospital, Detroit

52242

University of Iowa Hospitals and Clinics, Iowa City

55455

University of Minnesota Medical School, Minneapolis

60068

Lutheran General Cancer Care Center, Park Ridge

60637

University of Chicago Cancer Research Center, Chicago

62201

Saint Mary's Hospital, East Saint Louis

65203

Ellis Fischel Cancer Center, Columbia

70121

Alton Ochsner Medical Foundation Hospital, New Orleans

73190

University of Oklahoma, Oklahoma City

77060

U.S. Oncology, Houston

80262

University of Colorado Cancer Center, Denver

91767

Wilshire Oncology Medical Center, Pomona

92868

Chao Family Comprehensive Cancer Center, Orange

94704

Alta Bates Comprehensive Cancer Center, Berkeley

98104

Swedish Hospital Tumor Institute, Seattle

90033-0800

USC/Norris Comprehensive Cancer Center, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94305-5317

Stanford University School of Medicine, Stanford

02111

New England Medical Center Hospital, Boston

75235-9032

University of Texas Southwestern Medical School, Dallas

T2N 4N2

Tom Baker Cancer Center - Calgary, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V3V 1Z2

British Columbia Cancer Agency - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

British Columbia Cancer Agency, Vancouver

R3E 0V9

Manitoba Cancer Treatment and Research Foundation, Winnipeg

E2L 4L2

Saint John Regional Hospital, Saint John

B3H 1V7

Nova Scotia Cancer Centre, Halifax

P3E 5J1

Northeastern Ontario Regional Cancer Centre, Sudbury, Greater Sudbury

L8V 5C2

Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

L5M 2N1

Credit Valley Hospital, Mississauga

K1H 8L6

Ottawa Regional Cancer Center - General Division, Ottawa

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

J1H 5N4

Centre Universitaire de Sante de l'Estrie, Fleurimont

H2W-W1T8

Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

Jewish General Hospital - Montreal, Montreal

G1R 2J6

Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AltaRex

INDUSTRY

NCT00003634 - Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy | Biotech Hunter | Biotech Hunter